Zobrazeno 1 - 10
of 3 382
pro vyhledávání: ''
Autor:
Sandro Roberto De Araujo Cavallero, Ray Antonio Manneh Kopp, Fernando Sabino Marques Monteiro, Rodrigo Nogueira Fogace, Diogo Assed Bastos, Fabio A.B. Schutz, Helena Paes de Almeida Saito, Pamela Salman Boghikian, Pedro Luiz Serrano Usón, Fernando C. Maluf, Fernando Vidigal de Pádua, Evanius Garcia Wiermann, Sergio Aguiar, Felipe Moraes Toledo Pereira, Mouna Ayadi, Fábio Roberto Kater, Diogo Augusto Rodrigues da Rosa, Ricardo Saraiva de Carvalho, Fernando Nunes Galvão de Oliveira, Francisco Javier Orlandi, Vinicius Carreira Souza, Silke Gillessen Sommer
Publikováno v:
JCO Global Oncology
PURPOSE International guideline recommendations may not always be extrapolated to developing countries where access to resources is limited. In metastatic castration-sensitive prostate cancer (mCSPC), there have been successful drug and imaging advan
Autor:
Apurva Sood, Bhagwant Rai Mittal, Rakesh Kapoor, Ashwani Sood, Rajesh Gupta, Divya Khosla, Swayamjeet Satapathy
Publikováno v:
JCO Global Oncology
PURPOSE To compare the efficacy and safety of 177Lu-DOTATATE plus radiosensitizing capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-
Autor:
Abhinav Zawar, Suresh Kumar Bondili, Manju Sengar, Lingaraj Nayak, Navin Khattry, Jayashree Thorat, Pradeep Ventrapati, Hashmukh Jain, Anant Gokarn, Sachin Punatar, Bhausaheb Bagal, Avinash Bonda
Publikováno v:
JCO Global Oncology
PURPOSE The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of
Autor:
Stefano Mangiola, Jeremy Grummet, Michael Kerger, Paul Ruljancich, Ryan Stuchbery, David Clarke, Justin S. Peters, Andrew Ryan, Niall M. Corcoran, Phillip Parente, Nicholas Howard, Christopher M. Hovens, Natalie Kurganovs, Sam Norden, Anthony J. Costello, Anne Ngyuen, Corrina A Grima, Patrick McCoy, Geoff Macintyre, Philip Dundee, Marek Cmero, Ken Chow
Publikováno v:
JCO Precision Oncology
PURPOSE Androgen receptor (AR) signaling is important in prostate cancer progression, and therapies that target this pathway have been the mainstay of treatment for advanced disease for over 70 years. Tumors eventually progress despite castration thr
Autor:
Gunhild Mari Mælandsmo, Ole Christian Lingjærde, Elin Borgen, Ingrid Hedenfalk, Anne Lise Børresen-Dale, Thomas Hatschek, Niklas Loman, Bjørn Naume, Mads H. Haugen, Øystein Garred, Olav Engebraaten, Gordon B. Mills
Publikováno v:
JCO Precision Oncology
PURPOSE Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such treatment. PATIENTS AND METHODS In the NeoAva phase II cl
Autor:
Tatiana Gamez, Carlos Vargas, Christian Rolfo, Pilar Archila, Luis Corrales, Oscar Arrieta, Claudio Martin, Jorge Otero, C. Sotelo, Hernán Carranza, Juan Esteban Garcia-Robledo, D. Mayorga, Luisa Ricaurte, Camila Ordóñez-Reyes, Lucia Zatarain Barron, L. Rojas, Rafael Rosell, Luis Mas, Alejandro Ruiz-Patiño, Maritza Bermudez, July Rodriguez, J. Ávila, Andrés F. Cardona, Gonzalo Recondo, Feliciano Barrón
Publikováno v:
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
La activación de BIM es esencial para la apoptosis desencadenada por el inhibidor de la tirosina quinasa (TKI) del receptor del factor de crecimiento epidérmico (EGFR) en el cáncer de pulmón de células no pequeñas (CPCNP) con mutación de EGFR.
Autor:
Kenneth K.-S. Ng, A. Iqbal, Mark G. Kris, Maria E. Arcila, Helena A. Yu, Linda Ahn, Jia Luo, Yosef Tobi, Sara A. Hayes, Alex Makhnin, Gregory J Riely
Publikováno v:
JCO Precision Oncology. :55-64
PURPOSE Inhibition of the MEK/ERK pathway is critical for Bcl-2-like protein 11 (BIM)-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-induced apoptosis, and dysregulation of this pathway may be a mechanism of acquired
Autor:
Mark G. Kris, Kavitha J Ramachandran, Michael Lanuti, Lecia V. Sequist, James Huang, Jamie E. Chaft, Joseph B. Shrager, Deepa Rangachari, Christopher G. Azzoli, Zofia Piotrowska, Mark S. Huberman, Daniel B. Costa, Alona Muzikansky, Joel W. Neal
Publikováno v:
JCO Precision Oncology. :325-332
PURPOSE For patients with surgically resected disease, multiple studies suggest a benefit of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in delaying cancer recurrence. The necessary duration of therapy for benefit is unk
Autor:
David Malka, Cedric Lecaille, Anne-Laure Bignon, Nicolas Williet, Caroline Pétorin, Thomas Aparicio, Jérôme Desramé, Jean-Marc Phelip, Côme Lepage, Eric Francois, Yves Rinaldi, Anthony Turpin, Prodige Investigators, Karine Le Malicot, Laetitia Dahan, Jean-François Seitz, Christine Rebischung, Olivier Bouché, Jean-Baptiste Bachet
Publikováno v:
Journal of Clinical Oncology. 39:3242-3250
PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over
Autor:
Philip He, Robin Kate Kelley, Ho Yeong Lim, Takuji Okusaka, Thomas Yau, David Wai-Meng Tai, Ghassan K. Abou-Alfa, Masafumi Ikeda, Bruno Sangro, Yoon-Koo Kang, Silvia Damian, Johanna C. Bendell, Mitesh J. Borad, William P. Harris, Tae-You Kim, Shukui Qin, Alejandra Negro, Mallory Makowsky, Nathan Standifer, Masatoshi Kudo, Ann-Lii Cheng, Jordi Bruix, Antonio Gasbarrini, Wei Peng Yong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 27
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unre